Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AARD Aardvark Therapeutics

Trading 06-09 11:50:33 EDT

3.51

-0.08

-2.23%

High3.73	Low3.49	Vol33.40K
Open3.58	D1 Closing3.59	Amplitude6.69%
Mkt Cap76.16M	Tradable Cap20.67M	Total Shares21.70M
T/O119.90K	T/O Rate0.57%	Tradable Shares5.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":3.51,"timestamp":1781020179316,"preClose":3.59,"halted":0,"volume":33404,"delay":0,"changeRate":-0.022284122562674116,"floatShares":5888000,"shares":21696893,"eps":-2.6398466,"marketStatus":"Trading","change":-0.08,"latestTime":"06-09 11:50:33 EDT","open":3.58,"high":3.73,"low":3.49,"amount":119900.2073668,"amplitude":0.066852,"askPrice":3.52,"askSize":221,"bidPrice":3.5,"bidSize":88,"shortable":3,"etf":0,"ttmEps":-2.6398466,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781035200000},"marketStatusCode":2,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":3.59,"preHourTrading":{"tag":"盘前","latestPrice":3.66,"preClose":3.59,"latestTime":"08:05 EDT","volume":105,"amount":383.950014,"timestamp":1781006733048,"change":0.07,"changeRate":0.019499,"amplitude":0.019499},"postHourTrading":{"tag":"盘后","latestPrice":3.55,"preClose":3.59,"latestTime":"18:07 EDT","volume":1309,"amount":4647.9,"timestamp":1780956433718,"change":-0.04,"changeRate":-0.011142,"amplitude":0.011142},"volumeRatio":0.714071,"impliedVol":1.3169,"impliedVolPercentile":0.5313},"requestUrl":"/m/hq/s/AARD/wiki","defaultTab":"wiki","newsList":[{"id":"2636122019","title":"FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2636122019","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636122019?lang=en_us&edition=fundamental","pubTime":"2026-05-18 05:06","pubTimestamp":1779051987,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst on May 15. Analyst Tazeen Ahmad from Bank of Ame...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/fda-clinical-hold-competitive-pressure-drive-aardvark-therapeutics-downgrade-as-price-target-slashed-from-18-to-4-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/fda-clinical-hold-competitive-pressure-drive-aardvark-therapeutics-downgrade-as-price-target-slashed-from-18-to-4-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635379037","title":"Aardvark Therapeutics downgraded to Underperform from Buy at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2635379037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635379037?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:00","pubTimestamp":1778875216,"startTime":"0","endTime":"0","summary":"BofA analyst Tazeen Ahmad downgraded Aardvark Therapeutics (AARD) to Underperform from Buy with a price target of $4, down from $18, following the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-downgraded-to-underperform-from-buy-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-downgraded-to-underperform-from-buy-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635343880","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2635343880","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635343880?lang=en_us&edition=fundamental","pubTime":"2026-05-16 02:20","pubTimestamp":1778869228,"startTime":"0","endTime":"0","summary":"LanzaTech Global  signed a securities purchase agreement with certain institutional investors to sell 2 million shares in a registered direct offering, targeting gross proceeds of about $20 million, the company said Friday.Shares sank 43% following an increase in intraday trading volume to almost 323,000 from a daily average of over 44,000.Aardvark Therapeutics  said the US Food and Drug Administration has placed a full clinical hold on its investigational new drug application for ARD-101, according to a company statement late Thursday.Morgan Stanley downgraded the stock to underweight from equalweight, and BTIG to neutral from buy.Shares of Aardvark slumped 31% as intraday trading volume advanced to more than 565,000 from a daily average of over 282,000.York Space Systems  reported a Q1 loss of $114.8 million, compared with a loss of $11.7 million a year earlier.Shares dropped 18%, with intraday trading volume at nearly 2.85 million, compared with a daily average of over 2.02 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LNZA","BK4187","BK4120","BK4007","AARD","YSS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635003161","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2635003161","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635003161?lang=en_us&edition=fundamental","pubTime":"2026-05-16 01:33","pubTimestamp":1778866395,"startTime":"0","endTime":"0","summary":"Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index falling 0.9% and the State Street Healthcare Select Sector SPDR ETF  shedding 0.8%.The iShares Biotechnology ETF  dropped 2.5%.In corporate news, Aardvark Therapeutics  shares fell 31% after the firm said the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101. Morgan Stanley downgraded the stock to underweight from equalweight, and BTIG to neutral from buy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2028103732.USD","LU2089283258.USD","LU2133065610.SGD","BK4007","LABU","LU0557290698.USD","LU1363072403.SGD","LU0314104364.USD","LU1244550577.SGD","LU0267386448.USD","LU0106831901.USD","LU1988902786.USD","LU1720051108.HKD","LU1548497426.USD","LU1989772923.USD","BK4137","LU1064131342.USD","LU0006306889.USD","BK4127","LU1244550221.USD","LU1668664300.SGD","LU1732799900.SGD","LU0029874061.USD","LU0106261372.USD","LU0158827781.USD","LU0528227936.USD","HCSG","LU1732800096.USD","LU1989772840.SGD","LU2089284900.SGD","IBB","BK4585","LU0225283273.USD","LU0320765646.SGD","LU0128526141.USD","LU1791710400.SGD","LU0882574139.USD","IE00BKVL7J92.USD","BK4581","BK4516","LU0795875169.SGD","LU2347655156.SGD","LU0795875086.SGD","AARD","BK4504","LU2271345857.HKD","XLV","XBI","LU1720051017.SGD","LU2023251221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035803","title":"Aardvark Therapeutics Cut to Neutral From Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035803","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635035803?lang=en_us&edition=fundamental","pubTime":"2026-05-15 22:52","pubTimestamp":1778856720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 10:52 ET (14:52 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635499033","title":"Aardvark Therapeutics Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2635499033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635499033?lang=en_us&edition=fundamental","pubTime":"2026-05-15 22:36","pubTimestamp":1778855816,"startTime":"0","endTime":"0","summary":"09:41 EDT Aardvark Therapeutics (AARD) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-inc-trading-resumes-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-inc-trading-resumes-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635809830","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:36 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2635809830","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635809830?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:36","pubTimestamp":1778852190,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:36 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nAQN2LZ6ZE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635808010","title":"Aardvark Therapeutics downgraded to Neutral from Buy at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2635808010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635808010?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:30","pubTimestamp":1778851850,"startTime":"0","endTime":"0","summary":"BTIG downgraded Aardvark Therapeutics (AARD) to Neutral from Buy with no price target after the FDA placed a full clinical hold on ARD-101. While m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-downgraded-to-neutral-from-buy-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-downgraded-to-neutral-from-buy-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635087277","title":"Aardvark Therapeutics Could Regain Investor Interest With Upcoming Results -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2635087277","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635087277?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:18","pubTimestamp":1778851080,"startTime":"0","endTime":"0","summary":"1318 GMT - Oppenheimer analysts say investors could show interest in Aardvark Therapeutics again if upcoming results for ARD-101, a treatment for people with the genetic disorder Prader-Willi Syndrome, show unequivocal efficacy. The analysts expect the company to unblind Phase 3 trial results in July after its application for the treatment was placed on clinical hold by the Food and Drug Administration. The trial's volume of placebo-controlled efficacy data could be sufficient to show whether its worthwhile to push ARD-101 forward, they say. \"We can envision a scenario in which a dose level capable of yielding disease benefit remains below that associated with the observed cardiac safety signal,\" the analysts say. \"While the implications of this safety signal to ARD-101's forward development remain unclear, we believe an unequivocal efficacy showing would be positively received by the market.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635090084","title":"Aardvark Therapeutics Inc : Btig Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635090084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635090084?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:33","pubTimestamp":1778848414,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nFWN41S1A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635608324","title":"Morgan Stanley Downgrades Aardvark Therapeutics to Underweight From Equalweight, Cuts Price Target to $3 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2635608324","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635608324?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:28","pubTimestamp":1778840929,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (AARD) has an average rating of overweight and mean price target of $18.45, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635722135","title":"Stocks to Watch: Figma, Aardvark, Gambling.com, P3 Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2635722135","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635722135?lang=en_us&edition=fundamental","pubTime":"2026-05-15 07:22","pubTimestamp":1778800920,"startTime":"0","endTime":"0","summary":"Figma raised its outlook, citing more customers for its AI products. Shares rose 12% to $22.69 in after-hours trading Thursday.Aardvark Therapeutics said the Food and Drug Administration put its drug on a clinical hold. The stock slid 18% to $5.52 after the bell.Gambling.com said it was cutting its guidance and reducing its workforce by 25%. Shares sank 29% to $2.96.P3 Health Partners raised its earnings outlook. The stock gained 46% to $5.90.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4539","PIII","FIGG","BK4009","BK4023","AARD","FIG","BK4007","GAMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635724673","title":"Aardvark Therapeutics announces FDA clinical hold on ARD-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2635724673","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635724673?lang=en_us&edition=fundamental","pubTime":"2026-05-15 06:08","pubTimestamp":1778796513,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (AARD) announced that the U.S. Food and Drug Administration has placed a full clinical hold on its investigational new drug a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-announces-fda-clinical-hold-on-ard-101-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-announces-fda-clinical-hold-on-ard-101-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","ARD","LABU","BK4585","AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635117729","title":"Aardvark Therapeutics Says FDA Placed Hold on ARD-101 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2635117729","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635117729?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:08","pubTimestamp":1778792880,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics' drug application for ARD-101, a treatment for people with the genetic disorder Prader-Willi Syndrome, was placed on clinical hold by the Food and Drug Administration.The clinical-stage biopharmaceutical company said after the close Thursday the hold applies to all ongoing clinical studies under the application, including two Phase 3 trials.Shares slid 14% to $5.82 in post-market trading.The hold was related to Aardvark's voluntary pause of one of the Phase 3 trials in February, which it said at the time was due to safety issues in the study.Aardvark is in talks with the FDA to resolve the hold and determine a path forward for ARD-101, it said. The company also plans to unblind the clinical data from both trials to assess efficacy and safety, which it said will help decide next steps for the program.ARD-101 is designed to suppress hunger for the treatment of Prader-Willi Syndrome and metabolic diseases.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","LABU","BK4588","AARD","ARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635726716","title":"FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2635726716","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635726716?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:51","pubTimestamp":1778791899,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics AARD.O on Thursday said the U.S. Food and Drug Administration placed a full clinical hold on its drug to treat extreme hunger linked to the rare disorder Prader-Willi syndrome, halting all late-stage trials.Shares of the company fell about 14% in after-hours trading.Aardvark had paused enrollment and dosing in February after it found heart-related side effects in healthy volunteers given higher-than-planned doses of the drug, ARD-101.The FDA's clinical hold applies to all studies on ARD-101, including a late-stage trial and extension study in Prader-Willi syndrome.The hold follows a previously announced voluntary pause, the company said, adding that it is in active discussions with the regulator to resolve the issue.The drug developer said that 68 patients were dosed in the main study and 19 in the extension as of late February.It added that it would review study data to assess safety and efficacy and determine next steps.Aardvark's ARD-101, being developed as an ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL4N41R1YO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635728796","title":"Aardvark Therapeutics Inc - to Unblind Hero and Ole Trial Data for Ard-101 for Assessment, Determine Next Steps for the Ard-101 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2635728796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635728796?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:01","pubTimestamp":1778788862,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA2SCRWX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635728266","title":"Aardvark Therapeutics Plans to Unblind Hero and Ole Data to Inform Path Forward Following FDA Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2635728266","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635728266?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:01","pubTimestamp":1778788862,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA2SCRWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635282247","title":"Aardvark Therapeutics Inc - FDA Places Full Clinical Hold on Aardvark's Ind for Ard-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2635282247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635282247?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:01","pubTimestamp":1778788862,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA2SCRWX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635251837","title":"Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2635251837","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635251837?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:01","pubTimestamp":1778788860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  14, 2026  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295315/0/en/Aardvark-Therapeutics-Plans-to-Unblind-HERO-and-OLE-Data-to-Inform-Path-Forward-Following-FDA-Clinical-Hold.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4588","BK4585","IND","PWS","BK4007","HERO","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216183","title":"Aardvark Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216183","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216183?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:59","pubTimestamp":1778587193,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryAardvark Therapeutics Inc AARD.OQ reported a quarterly adjusted loss of 99 cents per share for the quarter en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P1LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://aardvarktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1003},{"period":"1month","weight":-0.3401},{"period":"3month","weight":-0.38},{"period":"6month","weight":-0.7432},{"period":"1year","weight":-0.696},{"period":"ytd","weight":-0.7265}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0022},{"period":"3month","weight":0.0916},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.2338},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Aardvark Therapeutics","nameEN":"Aardvark Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aardvark Therapeutics(AARD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aardvark Therapeutics,AARD,Aardvark Therapeutics股票,Aardvark Therapeutics股票老虎,Aardvark Therapeutics股票老虎国际,Aardvark Therapeutics行情,Aardvark Therapeutics股票行情,Aardvark Therapeutics股价,Aardvark Therapeutics股市,Aardvark Therapeutics股票价格,Aardvark Therapeutics股票交易,Aardvark Therapeutics股票购买,Aardvark Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aardvark Therapeutics(AARD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aardvark Therapeutics(AARD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction